Abstract ID	Abstract Title	Presentation ID	Session	Category	Presenting Order	Session Date	Session Time
210153	Gene skipping of Factor VIII Gene Transcript as a Future Treatment for Haemophilia A	O1-01	Oral Communication 1	Hemophilia and Bleeding Disorders	1	June 29 (Fri.)	9:00 - 10:00
210187	Genotype Analysis of Hemophilia B Patients in Taiwan	O1-02	Oral Communication 1	Hemophilia and Bleeding Disorders	2	June 29 (Fri.)	9:00 - 10:00
210136	Modified Thromboelastography- A method for the diagnosis and subtyping of von Willebrand disease	O1-03	Oral Communication 1	Hemophilia and Bleeding Disorders	3	June 29 (Fri.)	9:00 - 10:00
210060	High-dose dexamethasone alters the increase in IL-16 level in adult immune thrombocytopenia	O1-04	Oral Communication 1	Hemophilia and Bleeding Disorders	4	June 29 (Fri.)	9:00 - 10:00
210147	A novel murine model of immune thrombocytopenia induced by immunized CD41-knockout mice	O1-05	Oral Communication 1	Hemophilia and Bleeding Disorders	5	June 29 (Fri.)	9:00 - 10:00
210077	Neutrophil activation by heparin induced thrombocytopenia antibodies is required for thrombus formation	O1-06	Oral Communication 1	Hemophilia and Bleeding Disorders	6	June 29 (Fri.)	9:00 - 10:00
210106	Pharmacokinetic profile of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgery	O1-07	Oral Communication 1	Hemophilia and Bleeding Disorders	7	June 29 (Fri.)	9:00 - 10:00
210070	Growth arrest-specific gene 6 receptors, Tyro3, Axl, and Mer, differentially participate in platelet activation and thrombus formation	O2-01	Oral Communication 2	Platelets and Cardiovascular Disorders	1	June 29 (Fri.)	10:00 - 11:00
210091	Familial platelet disorder with predisposition to myeloid malignancy (FPDMM); atypical phenotypes of RUNX1 gene variants	O2-02	Oral Communication 2	Platelets and Cardiovascular Disorders	2	June 29 (Fri.)	10:00 - 11:00
210006	Recombinant Thrombomodulin (rTM) Reduced Neutrophil Extracellular Trap (NET) Formation and Improved Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis in Murine Models	O2-03	Oral Communication 2	Platelets and Cardiovascular Disorders	3	June 29 (Fri.)	10:00 - 11:00
210170	High-molecular-weight kininogen improves host defense during Gram- negative sepsis	O2-04	Oral Communication 2	Platelets and Cardiovascular Disorders	4	June 29 (Fri.)	10:00 - 11:00
210007	Targeted microbubbles loaded with microRNA for a theranostic approach of abdominal aortic aneurysms	O2-05	Oral Communication 2	Platelets and Cardiovascular Disorders	5	June 29 (Fri.)	10:00 - 11:00
210188	Kallistatin-Sirtuin 1 pathway is crucial in limiting abdominal aortic aneurysm progression	O2-06	Oral Communication 2	Platelets and Cardiovascular Disorders	6	June 29 (Fri.)	10:00 - 11:00
210008	Nanoliposomes for Safe and Efficient Therapeutic CD39 mRNA Delivery: Prevention and Treatment ofInflammatory and Cardiovascular Diseases	O2-07	Oral Communication 2	Platelets and Cardiovascular Disorders	7	June 29 (Fri.)	10:00 - 11:00
210093	NLRP3 regulates platelet integrin aIIbb3 outside-in signaling, hemostasis and arterial thrombosis	O3-01	Oral Communication 3	Platelets	1	June 29 (Fri.)	13:20 - 14:20
210029	Migfilin regulates hemostasis and thrombus formation through affecting platelet $\alpha_{llb}\beta_3$ outside-in signaling.	O3-02	Oral Communication 3	Platelets	2	June 29 (Fri.)	13:20 - 14:20
210152	Induced pluripotent stem cells from Bernard Soulier syndrome patients as a disease model to study the mechanisms of macrothrombocytopenia	O3-03	Oral Communication 3	Platelets	3	June 29 (Fri.)	13:20 - 14:20
210167	The transmembrane thiol isomerase TMX1 is a strong negative regulator of platelet function	O3-04	Oral Communication 3	Platelets	4	June 29 (Fri.)	13:20 - 14:20
210004	A role of Pyk2 in regulation of platelet shape change downstream of $G_{12/13}$ pathways	O3-05	Oral Communication 3	Platelets	5	June 29 (Fri.)	13:20 - 14:20
210030	Platelet Peroxisome Proliferator-activated Receptor α is involved in hemostasis and thrombus formation	O3-06	Oral Communication 3	Platelets	6	June 29 (Fri.)	13:20 - 14:20
210148	Characterization of a Heparin-Independent Monoclonal Antibody that Causes Heparin-Induced Thrombocytopenia	O3-07	Oral Communication 3	Platelets	7	June 29 (Fri.)	13:20 - 14:20
210124	Achievement of normal factor VIII activity following gene transfer with valoctocogene roxaparvovec (BMN 270): Long-term efficacy and safety results in patients with severe hemophilia A	O4-01	Oral Communication 4	Hemophilia	1	June 29 (Fri.)	14:20 - 15:20
210033	The origin and occurrence of de novo mutation in hemophilia A without prior family history	O4-02	Oral Communication 4	Hemophilia	2	June 29 (Fri.)	14:20 - 15:20
210183	Influence of Genetic Polymorphisms of Biological Mediators on the Phenotypic Heterogeneity in Hemophilic Arthropathy	O4-03	Oral Communication 4	Hemophilia	3	June 29 (Fri.)	14:20 - 15:20
210171	FVIII Gene Mutation In Paediatric Severe Haemophilia A With Inhibitors And Respond To Immune Tolerance Induction. A Single Centre. Azmanira Aziz, Faraizah Abdul Karim, National Blood Centre, Kuala Lumpur	O4-04	Oral Communication 4	Hemophilia	4	June 29 (Fri.)	14:20 - 15:20
210086	Discrepancies between the results of one-stage clotting assays and the chromogenic assay in hemophilia A patients	O4-05	Oral Communication 4	Hemophilia	5	June 29 (Fri.)	14:20 - 15:20
210111	Use of the HEAD-US in a Haemophilia Treatment Centre	O4-06	Oral Communication 4	Hemophilia	6	June 29 (Fri.)	14:20 - 15:20
210080	Low-dose ITI strategy for high-titer inhibitor hemophilia A children with poor ITI risk in China	O4-07	Oral Communication 4	Hemophilia	7	June 29 (Fri.)	14:20 - 15:20
210005	Alterations of plasma miRNA 122 and its correlation with other hematologic variables in patients undergoing repeated phlebotomy	O5-01	Oral Communication 5	Transfusion and Monitoring	1	June 29 (Fri.)	15:30 - 16:30
210120	Knowledge, Attitude and Practice of Blood Donation among First Year Medical Students at the Faculty of Medicine and Surgery of the University of Santo Tomas	O5-02	Oral Communication 5	Transfusion and Monitoring	2	June 29 (Fri.)	15:30 - 16:30
210038	Knowledge, Attitudes And Practices On Blood Transfusion Of Medical Residents In A Tertiary Hospital: A Questionnaire-Based Study	O5-03	Oral Communication 5	Transfusion and Monitoring	3	June 29 (Fri.)	15:30 - 16:30
210158	Comparison between Japanese obstetrical DIC score and the pregnancy modified ISTH DIC score for obstetric DIC cases	O5-04	Oral Communication 5	Transfusion and Monitoring	4	June 29 (Fri.)	15:30 - 16:30
210190	The Strength of ABO Blood Typing in Patients with Incompatibility Crossmatch Dr.Nadjwa Zamalek Dalimoenthe, SpPK-KDr Hasan Sadikin HospitalBandung Indonesia	O5-05	Oral Communication 5	Transfusion and Monitoring	5	June 29 (Fri.)	15:30 - 16:30

210069	Monitoring of Anticoagulation for Adults Undergoing Cardiopulmonary Bypass in Cardiac Surgery	O5-06	Oral Communication 5	Transfusion and Monitoring	6	June 29 (Fri.)	15:30 - 16:30
210104	Monitoring treatments by unfractionated heparin (UFH). Stability of plasma anti-Xa activity for up to 4 hours in citrated tubes	O5-07	Oral Communication 5	Transfusion and Monitoring	7	June 29 (Fri.)	15:30 - 16:30
210003	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone	O6-01	Oral Communication 6	Management of Thromboembolism	1	June 30 (Sat.)	14:10 - 15:10
210129	The Promotion and Exploration of Venous Thromboembolism Prevention and Treatment System and Caprini Risk Model in the Area of Leshan, Sichuan Province	O6-02	Oral Communication 6	Management of Thromboembolism	2	June 30 (Sat.)	14:10 - 15:10
210151	Early thrombosis of the portal venous system after splenectomy for thalassemia major	O6-03	Oral Communication 6	Management of Thromboembolism	3	June 30 (Sat.)	14:10 - 15:10
210048	Morbidity and mortality in patients with antiphospholipid syndrome: a longitudinal cohort study of Japanese patients	O6-04	Oral Communication 6	Management of Thromboembolism	4	June 30 (Sat.)	14:10 - 15:10
210199	Establishing an integrated diagnostic pathway for suspected platelet bleeding disorders	O6-05	Oral Communication 6	Management of Thromboembolism	5	June 30 (Sat.)	14:10 - 15:10
210101	An investigation of hypofibrinogenemia and decreased antithrombin levels in the post-marketing surveillance of recombinant human thrombomodulin for disseminated intravascular coagulation	O6-06	Oral Communication 6	Management of Thromboembolism	6	June 30 (Sat.)	14:10 - 15:10
210155	Venous thromboembolism in Asia and worldwide: Emerging insights from the GARFIELD-VTE registry	O6-07	Oral Communication 6	Management of Thromboembolism	7	June 30 (Sat.)	14:10 - 15:10
210042	Clinical relevance of testing IgM phosphatidylserine-dependent antiprothrombin antibodies	O7-01	Oral Communication 7	Clinical Hemostasis and Thrombosis	1	June 30 (Sat.)	15:10 - 16:10
210176	Successful International Standardised Study of ADAMTS13 Assays - Results from the Asia-Pacific Microangiopathic Thrombocytopenia (APMAT) Network	O7-02	Oral Communication 7	Clinical Hemostasis and Thrombosis	2	June 30 (Sat.)	15:10 - 16:10
210066	Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and TM in disseminated intravascular coagulation: a multi-center prospective observational study	O7-03	Oral Communication 7	Clinical Hemostasis and Thrombosis	3	June 30 (Sat.)	15:10 - 16:10
210179	The effect of bacterial infection on APTT-based clot waveform analysis	O7-04	Oral Communication 7	Clinical Hemostasis and Thrombosis	4	June 30 (Sat.)	15:10 - 16:10
210182	The comparison between fibrin monomer complex and soluble fibrin reagents in thrombosis markers from the view of fibrinolysis proceeding situation	O7-05	Oral Communication 7	Clinical Hemostasis and Thrombosis	5	June 30 (Sat.)	15:10 - 16:10
210075	The combination of Caprini risk assessment scale and thrombosis biomarkers for evaluating the risk of venous thromboembolism in critically ill patients	O7-06	Oral Communication 7	Clinical Hemostasis and Thrombosis	6	June 30 (Sat.)	15:10 - 16:10
210059	Antiphospholipid scoring is predictive for the development of atherosclerosis in systemic lupus erythematosus patients.	O7-07	Oral Communication 7	Clinical Hemostasis and Thrombosis	7	June 30 (Sat.)	15:10 - 16:10